[1] Kishore A, Vail A, Majid A, et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis [J]. Stroke, 2014, 45(2): 520-526. [2] Saada F, Antonios N. Existence of ipsilateral hemiparesis in ischemic and hemorrhagic stroke: two case reports and review of the literature [J]. Eur Neurol, 2014, 71(1-2): 25-31. [3] Winship IR, Armitage GA, Ramakrishnan G, et al. Augmenting collateral blood flow during ischemic stroke via transient aortic occlusion [J]. J Cereb Blood Flow Metab, 2014, 34(1): 61-71. [4] Marks MP, Lansberg MG, Mlynash M, et al. Effect of collateral blood flow on patients undergoing endovascular therapy for acute ischemic stroke [J]. Stroke, 2014, 45(4): 1035-1039. [5] Zhao H, Cheng L, Liu Y, et al. Mechanisms of anti-inflammatory property of conserved dopamine neurotrophic factor: inhibition of JNK signaling in lipopolysaccharide-induced microglia [J]. J Mol Neurosci, 2014, 52(2): 186-192. [6] Sieweke MH, Allen JE. Beyond stem cells: self-renewal of differentiated macrophages [J]. Science, 2013, 342(6161): 1242974. [7] Geissmann F. Development of monocytes, macrophages, and dendritic cells (vol 327, pg 656, 2010) (Erratum) [J]. Science, 2010, 330(6009): 1318. [8] Ginhoux F, Greter M, Leboeuf M, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages [J]. Science, 2010, 330(6005): 841-845. [9] Kierdorf K, Erny D, Goldmann T, et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways [J]. Nat Neurosci, 2013, 16(3): 273-280. [10] Schulz C, Perdiguero EG, Chorro L, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells [J]. Science, 2012, 336(6077): 86-90. [11] Parkhurst CN, Yang G, Ninan I, et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor [J]. Cell, 2013, 155(7): 1596-1609. [12] Li T, Pang S, Yu Y, et al. Proliferation of parenchymal microglia is the main source of microgliosis after ischaemic stroke [J]. Brain, 2013, 136(Pt 12): 3578-3588. [13] Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases [J]. Mol Neurobiol, 2016, 53(2): 1181-1194. [14] Tang XN, Cairns B, Kim JY, et al. NADPH oxidase in stroke and cerebrovascular disease [J]. Neurol Res, 2012, 34(4): 338-345. [15] Tang XN, Zheng Z, Giffard RG, et al. Significance of marrow-derived nicotinamide adenine dinucleotide phosphate oxidase in experimental ischemic stroke [J]. Ann Neurol, 2011, 70(4): 606-615. [16] Radermacher KA, Wingler K, Langhauser F, et al. Neuroprotection after stroke by targeting NOX4 as a source of oxidative stress [J]. Antioxid Redox Signal, 2013, 18(12): 1418-1427. [17] Ginsberg MD. Expanding the concept of neuroprotection for acute ischemic stroke: The pivotal roles of reperfusion and the collateral circulation [J]. Prog Neurobiol, 2016, 145-146: 46-77. [18] Guix FX, Uribesalgo I, Coma M, et al. The physiology and pathophysiology of nitric oxide in the brain [J]. Prog Neurobiol, 2005, 76(2): 126-152. [19] Lakhan SE, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches [J]. J Transl Med, 2009, 7: 97. [20] Terpolilli NA, Moskowitz MA, Plesnila N. Nitric oxide: considerations for the treatment of ischemic stroke [J]. J Cereb Blood Flow Metab, 2012, 32(7): 1332-1346. [21] Cho S, Park EM, Zhou P, et al. Obligatory role of inducible nitric oxide synthase in ischemic preconditioning [J]. J Cereb Blood Flow Metab, 2005, 25(4): 493-501. [22] Lapi D, Colantuoni A. Remodeling of cerebral microcirculation after ischemia-reperfusion [J]. J Vasc Res, 2015, 52(1): 22-31. [23] Boscia F, Esposito CL, Casamassa A, et al. The isolectin IB4 binds RET receptor tyrosine kinase in microglia [J]. J Neurochem, 2013, 126(4): 428-436. [24] Miao X, Liu X, Yue Q, et al. Deferoxamine suppresses microglia activation and protects against secondary neural injury after intracerebral hemorrhage in rats [J]. Nan Fang Yi Ke Da Xue Xue Bao, 2012, 32(7): 970-975. [25] Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator [J]. Neurobiol Dis, 2010, 38(3): 376-385. [26] Chaturvedi M, Kaczmarek L. MMP-9 inhibition: a therapeutic strategy in ischemic stroke [J]. Mol Neurobiol, 2014, 49(1): 563-573. [27] Chen Z, Jalabi W, Shpargel KB, et al. Lipopolysaccharide-induced microglial activation and neuroprotection against experimental brain injury is independent of hematogenous TLR4 [J]. J Neurosci, 2012, 32(34): 11706-11715. [28] Napoli I, Neumann H. Protective effects of microglia in multiple sclerosis [J]. Exp Neurol, 2010, 225(1): 24-28. [29] Kong Y, Le Y. Toll-like receptors in inflammation of the central nervous system [J]. Int Immunopharmacol, 2011, 11(10): 1407-1414. [30] Lin S, Yin Q, Zhong Q, et al. Heme activates TLR4-mediated inflammatory injury via MyD88/TRIF signaling pathway in intracerebral hemorrhage [J]. J Neuroinflammation, 2012, 9: 46. [31] Zhang D, Li H, Li T, et al. TLR4 inhibitor resatorvid provides neuroprotection in experimental traumatic brain injury: implication in the treatment of human brain injury [J]. Neurochem Int, 2014, 75: 11-18. [32] Mandrekar-Colucci S, Sauerbeck A, Popovich PG, et al. PPAR agonists as therapeutics for CNS trauma and neurological diseases [J]. ASN Neuro, 2013, 5(5): e00129. [33] Quintanilla RA, Utreras E, Cabezas-Opazo FA. Role of PPAR gamma in the differentiation and function of neurons [J]. PPAR Res, 2014, 2014: 768594. [34] Zhao X, Strong R, Zhang J, et al. Neuronal PPAR gamma deficiency increases susceptibility to brain damage after cerebral ischemia [J]. J Neurosci, 2009, 29(19): 6186-6195. [35] Rivera A, Vanzulli I, Butt AM. A central role for ATP signaling in glial interactions in the CNS [J]. Curr Drug Targets, 2016, 17(16): 1829-1833. [36] Bhattacharya A, Biber K. The microglial ATP-gated ion channel P2X7 as a CNS drug target [J]. Glia, 2016, 64(10): 1772-1787. [37] Rech JC, Bhattacharya A, Letavic MA, et al. The evolution of P2X7 antagonists with a focus on CNS indications [J]. Bioorg Med Chem Lett, 2016, 26(16): 3838-3845. [38] Engel T. Purinergic signaling-induced neuroinflammation and status epilepticus [J]. Expert Rev Neurother, 2016, 16(7): 735-737. |